Stock Financial Ratios

NLNK / NewLink Genetics Corp financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)287.72
Enterprise Value ($M)187.52
Book Value ($M)129.47
Book Value / Share4.47
Price / Book2.70
NCAV ($M)130.08
NCAV / Share4.49
Price / NCAV-8.41
Income Statement (mra) ($M)
Net Income-85.16
Balance Sheet (mrq) ($M)
Cash & Equivalents120.70
Cash / Share4.17
Quick Ratio4.43
Current Ratio4.43
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.66
Return on Assets (ROA)-0.51
Return on Equity (ROE)-0.66
Identifiers and Descriptors
Central Index Key (CIK)1126234
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)37.08
Scoring Models
Piotroski F Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Cash And Equivalents Per Share4.17
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Accumulated Depreciation And Depletion Per Share0.23
Accounts Payable Per Share0.00
Debt Per Share0.00
Liabilities And Stock Equity Per Share4.82
Inventory Per Share0.00
Liabilities Per Share0.94
Assets Other Non Current Per Share0.00
Intangibles Per Share0.00
Cash Per Share4.17
Goodwill Per Share0.00
Property Plant And Equipment Per Share0.19
Equity Per Share3.67
Additional Paid In Capital Per Share11.42
Liabilities Current Per Share0.90
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Accounts Receivable Per Share0.00
Treasury Stock Per Share0.04
Inventory Raw Materials Per Share0.00
Retained Earnings Per Share-7.72
Assets Other Current Per Share0.00
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Per Share-0.23
Property Plant And Equipment Net Per Share-0.23
Assets Current Per Share0.00
Minority Interest Per Share0.00

Related News Stories

Bristol-Myers Squibb Brings Out Its Ace Card In The Midst Of An IDO Inhibitor Battle

2017-11-13 seekingalpha
Bristol-Myers Squibb released positive results in an early-stage study using an IDO inhibitor drug in combination with Opdivo in both bladder and cervical cancer patients. (116-1)

NewLink Genetics Corporation 2017 Q3 - Results - Earnings Call Slides

2017-11-05 seekingalpha
The following slide deck was published by NewLink Genetics Corporation in conjunction with their 2017 Q3 earnings call. (27-0)

NewLink Genetics' (NLNK) CEO Charles Link on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good day, ladies and gentlemen, and welcome to the NewLink Genetics Third Quarter 2017 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. (62-0)

Biotech Forum Daily Digest: Aratana Therapeutics Back In The Spotlight

2017-10-16 seekingalpha
The biotech sector will try to overcome some late weakness last week as trading opens today. (277-3)

Your Daily Pharma Scoop: Synergy's Cash Position, Flexion's Zilretta Approval, Keryx Major Catalyst

2017-10-10 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (963-5)

CUSIP: 651511107